Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Treasury	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance, shares (in shares) at Dec. 31, 2018			586,881,720	549,907
Beginning balance at Dec. 31, 2018	$ 1,791,291	$ 0	$ 5,869	$ (1,791)	$ 3,004,422	$ (926)	$ (20,131)	$ (1,197,078)	$ 926
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	13,421				13,421
Exercise of common stock options and warrants (in shares)			19,232
Exercise of common stock options and warrants	(3)				(3)
Conversion of 2025 convertible notes (in shares)			29,250,000
Conversion of 2025 convertible notes	50,852		$ 293		50,559
Sale of common stock (in shares)			54,227,749
Sale of common stock	76,062		$ 542		75,520
Net income (loss)	(314,925)							(314,925)
Other comprehensive loss	(1,939)						(1,939)
Ending balance, shares (in shares) at Dec. 31, 2019			670,378,701	549,907
Ending balance at Dec. 31, 2019	$ 1,614,759	$ (1,342)	$ 6,704	$ (1,791)	3,142,993		(22,070)	(1,511,077)	$ (1,342)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	Accounting Standards Update 2016-13 [Member]
Equity-based compensation expense	$ 8,947				8,947
Exercise of common stock options and warrants (in shares)			206,875
Exercise of common stock options and warrants	756		$ 2		754
Net income (loss)	30,586							30,586
Other comprehensive loss	17,845						17,845
Ending balance, shares (in shares) at Dec. 31, 2020			670,585,576	549,907
Ending balance at Dec. 31, 2020	1,671,551		$ 6,706	$ (1,791)	3,152,694		(4,225)	(1,481,833)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	$ 13,632				13,632
Exercise of common stock options and warrants (in shares)	445,437		445,437
Exercise of common stock options and warrants	$ 1,081		$ 5		1,076
Conversion of 2025 convertible notes (in shares)			19,051,270	8,105,175
Conversion of 2025 convertible notes	55,275		$ 190		55,085
Net income (loss)	(30,143)							(30,143)
Other comprehensive loss	(26,270)						(26,270)
Ending balance, shares (in shares) at Dec. 31, 2021			690,082,283	8,655,082
Ending balance at Dec. 31, 2021	$ 1,685,126		$ 6,901	$ (1,791)	$ 3,222,487		$ (30,495)	$ (1,511,976)